Address: 72 Steel Road Spartan , Kempton Park ,South Africa
Tel: +27 11975 0654
Sandoz, the generic pharmaceuticals division of the Novartis Group, is a global leader in the rapidly growing generics industry. With quality going back to its roots in the 19th century, Sandoz has a strong global presence covering 90% of the world’s population. We are committed to providing healthcare products and services of a consistently high standard, worldwide. We believe that consistent and reliable quality is what sets us apart from our competition, by offering customers the safety and efficacy associated with reference medicines, at lower cost.
At Sandoz we make far more than just traditional off-patent medicines. We develop and manufacture a wide range of difficult-to-make medicines, ranging from complex delivery systems for standard generics through to modern biopharmaceutical medicines (biosimilars).
Adhering to one, uniform standard, Sandoz South Africa supplies a comprehensive range of medicines for just about every therapeutic area, from Cardiovascular, Anti-Infectives, CNS, Analgesics, and the challenging field of TB.
Our core business lies in the development, production and distribution of high-quality, affordable generic medicines. We offer approximately 1 000 generic compounds worldwide and are a leading provider of differentiated, value-added products, including state-of-the-art biosimilars, injectables, inhalers and transdermal patches.
The managing director at Adcock Ingram Critical Care reveals the company’s unique business model. As a long-established division within Adcock Ingram, Critical Care operates with relative independence. What is the relationship…
The head of operations of Hetero South Africa talks about the need for a more efficient regulatory system with a fast track process for essential molecules, and how Hetero is…
The CEO of Ascendis Health talks about their business model, being a long-term investment company that brings together healthy businesses in the healthcare industry, and how the diversification of their product…
Merck’s managing director for South Africa and general manager for Southeast Africa reveals why the company takes a long-term perspective when investing in African countries, helping to shape healthcare systems,…
The general manager of Novagen Pharma reveals how they are the second largest supplier of ARVs within the private South African market, how there is much room for the generics…
The country manager and Global Established Products Business Lead at Pfizer South Africa reveals how the private sector is committed to expanding healthcare for South Africans, why her ambition is…
The country manager of Dr. Reddy´s South Africa explains that while the perception of the quality of generics has improved in South Africa, there is still a long way to…
The CEO of NAPM reveals how the main challenge facing his members is the length of time needed to register a generic product, taking up to four years and acting…
South Africa has recently achieved the 1st Millennium Development Goal (MDG) – reducing the proportion of the population living on less than 1 USD a day by half – but…
Our international readers know about South Africa’s socio-economic relative achievements, considering the country joined the BRICS grouping last year and achieved the first Millennium Development Goal (MDG) that same year.…
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
The story of Novo Nordisk South Africa began in 1959 in Johannesburg. It was among the first affiliates outside of Denmark, with insulin and anti-infectives produced locally. To what extent…
See our Cookie Privacy Policy Here
